T. Rowe Price Associates
TVTX icon

T. Rowe Price Associates’s Travere Therapeutics TVTX Stock Holding History

T. Rowe Price Associates’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12M Buy
404,805
+9,961
+3% +$298K ﹤0.01% 1172
2025
Q4 		$15.1M Buy
394,844
+315,400
+397% +$10.3M ﹤0.01% 1132
2025
Q3 		$1.9M Buy
79,444
+8,072
+11% +$152K ﹤0.01% 1754
2025
Q2 		$1.06M Buy
71,372
+18,063
+34% +$299K ﹤0.01% 1966
2025
Q1 		$956K Buy
53,309
+13,705
+35% +$278K ﹤0.01% 1981
2024
Q4 		$690K Sell
39,604
-241,745
-86% -$4.28M ﹤0.01% 2140
2024
Q3 		$3.94M Buy
281,349
+247,908
+741% +$2.58M ﹤0.01% 1374
2024
Q2 		$275K Buy
33,441
+2,432
+8% +$16.4K ﹤0.01% 2456
2024
Q1 		$240K Buy
31,009
+2,948
+11% +$24.9K ﹤0.01% 2536
2023
Q4 		$253K Buy
28,061
+1,229
+5% +$8.95K ﹤0.01% 2449
2023
Q3 		$240K Sell
26,832
-10,319
-28% -$146K ﹤0.01% 2436
2023
Q2 		$571K Buy
37,151
+5,861
+19% +$107K ﹤0.01% 2061
2023
Q1 		$704K Buy
31,290
+2,292
+8% +$48.7K ﹤0.01% 1959
2022
Q4 		$610K Sell
28,998
-1,976
-6% -$41.9K ﹤0.01% 2043
2022
Q3 		$764K Buy
30,974
+4,106
+15% +$106K ﹤0.01% 1902
2022
Q2 		$651K Buy
26,868
+10,382
+63% +$261K ﹤0.01% 2100
2022
Q1 		$425K Buy
16,486
+2,289
+16% +$60.8K ﹤0.01% 2411
2021
Q4 		$441K Buy
+14,197
New +$400K ﹤0.01% 2447
2018
Q1 		– Sell
-286,201
Closed -$6.03M – 2583
2017
Q4 		$6.03M Sell
286,201
-60,500
-17% -$1.38M ﹤0.01% 1412
2017
Q3 		$8.63M Buy
346,701
+1,907
+0.6% +$42K ﹤0.01% 1357
2017
Q2 		$6.69M Sell
344,794
-155,616
-31% -$2.82M ﹤0.01% 1376
2017
Q1 		$9.24M Sell
500,410
-136,900
-21% -$2.68M ﹤0.01% 1347
2016
Q4 		$12.1M Sell
637,310
-211,560
-25% -$4.33M ﹤0.01% 1278
2016
Q3 		$19M Buy
848,870
+140,181
+20% +$2.67M ﹤0.01% 1151
2016
Q2 		$12.6M Sell
708,689
-15,100
-2% -$244K ﹤0.01% 1244
2016
Q1 		$9.89M Buy
723,789
+5,700
+0.8% +$86.5K ﹤0.01% 1274
2015
Q4 		$13.9M Sell
718,089
-2,000
-0.3% -$40K ﹤0.01% 1200
2015
Q3 		$14.6M Sell
720,089
-27,111
-4% -$803K ﹤0.01% 1199
2015
Q2 		$24.8M Hold
747,200
– – 0.01% 1071
2015
Q1 		$17.9M Buy
+747,200
New +$11.4M ﹤0.01% 1168

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

T. Rowe Price Associates's TVTX Position: Q1 2026 in Review

T. Rowe Price Associates increased its Travere Therapeutics (TVTX) stake by 2.5% in Q1 2026, buying an estimated $298K and bringing the position to 404,805 shares worth $12M. The position accounts for ﹤0.01% of the portfolio, ranked #1172.

T. Rowe Price Associates first reported a position in TVTX in Q1 2015 and has held it in 30 quarters since. The position peaked at $24.8M in Q2 2015. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • T. Rowe Price Associates held 404,805 shares of Travere Therapeutics worth $12M as of Q1 2026.
  • T. Rowe Price Associates bought 9,961 Travere Therapeutics shares in Q1 2026, an estimated $298K.
  • Travere Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #1172 holding.
  • T. Rowe Price Associates first reported a position in Travere Therapeutics in Q1 2015 and has held it in 30 quarters since.
  • T. Rowe Price Associates's Travere Therapeutics position peaked at $24.8M in Q2 2015.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.